These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 7983499

  • 1. Comparison of broth dilution and semisolid agar dilution for in vitro susceptibility testing of Cryptococcus neoformans.
    Del Poeta M, Barchiesi F, Morbiducci V, Arzeni D, Marinucci G, Ancarani F, Scalise G.
    J Chemother; 1994 Jun; 6(3):173-6. PubMed ID: 7983499
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
    Aller AI, Martín-Mazuelos E, Gutiérrez MJ, Bernal S, Chávez M, Recio FJ.
    J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
    [Abstract] [Full Text] [Related]

  • 3. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
    Warnock DW, Johnson EM, Rogers TR.
    J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
    [Abstract] [Full Text] [Related]

  • 4. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A, Pekmezović M, Barać A, Crnčević Radović L, Arsić Arsenijević V.
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [Abstract] [Full Text] [Related]

  • 5. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H.
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [Abstract] [Full Text] [Related]

  • 6. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC.
    Fromtling RA, Abruzzo GK, Bulmer GS.
    Mycopathologia; 1986 Apr; 94(1):27-30. PubMed ID: 3014339
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Two-site comparison of broth microdilution and semisolid agar dilution methods for susceptibility testing of Cryptococcus neoformans in three media.
    Anaissie E, Shawar R, Paetznick V, Ensign LG, Witte Z, LaRocco M.
    J Clin Microbiol; 1993 May; 31(5):1370-2. PubMed ID: 8501245
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method.
    López-Jodra O, Torres-Rodríguez JM, Méndez-Vásquez R, Ribas-Forcadell E, Morera-López Y, Baró-Tomás T, Alia-Aponte C.
    J Antimicrob Chemother; 2000 May; 45(5):645-9. PubMed ID: 10797087
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
    Kantarcioğlu AS, Boekhout T, Yücel A, Altas K.
    Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
    [Abstract] [Full Text] [Related]

  • 17. Effect of media on growth rate and susceptibility testing of Cryptococcus neoformans.
    St-Germain G, Dion C.
    Mycoses; 1996 Mar; 39(5-6):201-6. PubMed ID: 8909030
    [Abstract] [Full Text] [Related]

  • 18. In vitro antifungal activity of the new triazole D0870 against Penicillium marneffei compared with that of amphotericin B, fluconazole, itraconazole, miconazole and flucytosine.
    Boon-Long J, Mekha N, Poonwan N, Kusum M, Mikami Y, Yazawa K, Konyama K.
    Mycoses; 1996 Mar; 39(11-12):453-6. PubMed ID: 9145003
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp.
    Barchiesi F, Tortorano AM, Di Francesco LF, Cogliati M, Scalise G, Viviani MA.
    J Antimicrob Chemother; 1999 Feb; 43(2):295-9. PubMed ID: 11252339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.